P0881 Effectiveness and Safety of Tofacitinib in Biologic-Naïve Elderly Patients with Ulcerative Colitis

作者
A Singh D.M.,Vandana Midha,A Bhardwaj,Rajesh Sharma,Dharmatma Singh,Rajesh Mahajan,Ajit Sood
出处
期刊:Journal of Crohn's and Colitis [Oxford University Press]
卷期号:19 (Supplement_1): i1675-i1675 被引量:1
标识
DOI:10.1093/ecco-jcc/jjae190.1055
摘要

Abstract Background The prevalence of ulcerative colitis (UC) is increasing in elderly populations, yet real-world data on the efficacy and safety of tofacitinib in this demographic remains limited. This study aimed to evaluate the real-world effectiveness and safety of tofacitinib in elderly patients (≥60 years) with moderate-to-severe UC treated at a tertiary care center in North India. Methods This cohort study was conducted at Dayanand Medical College and Hospital, Ludhiana, from July 2022 to June 2024. Elderly patients (aged ≥60 years) with moderate-to-severe UC refractory to conventional therapies were included. Patients received tofacitinib at a dose of 10 mg twice daily for induction, followed by 5 mg twice daily for maintenance, and were assessed at weeks 8 and 52. The primary outcome was steroid-free remission at both weeks 8 and 52. Secondary outcomes included clinical remission (partial Mayo score ≤1), clinical response (≥3-point reduction in partial Mayo score), and steroid-free remission at individual time points. Adverse events were systematically recorded. Results A total of 35 patients (median age: 64 years, 40% male) were analyzed. Most patients (80%, n=28) had left-sided colitis. The primary outcome of steroid-free clinical remission at both weeks 8 and 52 was achieved in 9 patients (25.71%). At week 8, clinical remission, steroid-free remission, and clinical response were observed in 18 (51.42%), 15 (42.85%), and 22 (62.85%) patients, respectively. At week 52, clinical remission and steroid-free remission were each achieved in 22 (62.85%) patients, while 27 (77.14%) patients demonstrated a clinical response. The most common adverse events included hair loss (17.14%, n=6), sadness of mood (11.42%, n=4), and dyslipidemia (8.57%, n=3). Three patients developed self-limiting herpes zoster infection, and one patient reported bilateral retinal vein occlusion. Conclusion Tofacitinib demonstrated favorable efficacy and safety in biologic-naïve elderly patients with moderate-to-severe UC. These findings highlight its potential as a viable treatment option for this growing and often underrepresented patient population.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
刚刚
1秒前
1秒前
1秒前
今后的应助被clevenx采纳,获得10
1秒前
积极牛青完成签到,获得积分10
2秒前
CodeCraft的应助被风趣的莞采纳,获得10
2秒前
cff完成签到,获得积分10
3秒前
辉099411发布了新的文献求助10
3秒前
3秒前
3秒前
酷波er的应助被taipingyang采纳,获得10
4秒前
米菲发布了新的文献求助10
4秒前
西原的橙果完成签到,获得积分10
4秒前
Elowen完成签到,获得积分20
5秒前
Jigsaw发布了新的文献求助10
5秒前
tanglu发布了新的文献求助10
5秒前
5秒前
呵呵贺哈完成签到 ,获得积分10
5秒前
6秒前
开放一德发布了新的文献求助10
6秒前
6秒前
Meiyu发布了新的文献求助10
6秒前
syvshc的应助被2206714632采纳,获得10
6秒前
dandelion发布了新的文献求助10
6秒前
想的美发布了新的文献求助10
7秒前
7秒前
开朗灵寒完成签到,获得积分10
8秒前
8秒前
海清河晏完成签到,获得积分10
9秒前
科研通AI6.2的应助被珉志采纳,获得10
10秒前
Akim的应助被朵拉A梦采纳,获得10
10秒前
whistle完成签到,获得积分10
10秒前
Jasper的应助被韦智杰采纳,获得10
11秒前
yuC完成签到,获得积分10
11秒前
梦雅完成签到,获得积分10
11秒前
oioiiio发布了新的文献求助10
11秒前
经十路以东的应助被Meiyu采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194107
求助须知:如何正确求助?哪些是违规求助? 9580062
关于积分的说明 21869017
捐赠科研通 7793713
什么是DOI,文献DOI怎么找? 3437523
关于科研通互助平台的介绍 2560962
邀请新用户注册赠送积分活动 2484264